Skip to content

Ketamine: all studies

Page 22 of 448: studies 211 to 220 of 4,475, newest first. Back to the ketamine overview

Research

Emerging new psychoactive ketamine analogues: patterns of use and health risks identified by the French Addictovigilance Network.

International Journal of Drug Policy July 1, 2026 Salim Mezaache, Liselotte Pochard, Hélène Peyrière et al.

Ketamine analogues are emerging dissociative substances structurally related to ketamine and increasingly detected on drug markets worldwide. This study aimed to characterize patterns of use, user profiles, and associated health outcomes in France. We conducted a retrospective analysis of cases involving ketamine analogues reported to the French Addictovigilance Network up to 31 December 2024....

DOI: 10.1016/j.drugpo.2026.105326 (opens in new tab) Full text (opens in new tab) Addictovigilance Chemsex Ketamine analogues New psychoactive substances +1

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)-ketamine: Investigating metabolite contribution to subjective effects.

British Journal of Clinical Pharmacology July 1, 2026 Marije E. Otto, Gabriël E. Jacobs, Joost C Van Mechelen et al.

Oral administration of (S)-ketamine for treatment-resistant depression (TRD), as alternative to the registered intranasal or off-label intravenous administrations, has high potential. However, it is characterized by an extensive first-pass metabolism, resulting in low (S)-ketamine exposure and high levels of active metabolites, including (S)-norketamine and (S)-hydroxynorketamine. The relative...

DOI: 10.1002/bcp.70503 (opens in new tab) Full text (opens in new tab) Pkpd model Norketamine Pharmacodynamics Pharmacokinetics +1

NADPH oxidase-1 suppression prolongs the antidepressant-like effect of ketamine.

Molecular Psychiatry July 1, 2026 Waki Nakajima, Tetsu Arisawa, Susumu Jitsuki et al. 1 citation

Subanesthetic doses of ketamine, a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist, produce rapid and robust antidepressant effects in patients with treatment-resistant depression (TRD). However, after a single administration, the therapeutic benefit is short-lived, and strategies to maintain its efficacy remain unclear. This study focused on the glutamate...

Autonomic-salience stability as a candidate Gate for awake low-dose ketamine: a systems neuroscience framework with a clinical anchor

Frontiers in Systems Neuroscience July 1, 2026 Kei Torii, Maho Jinno

Ketamine responses vary across patients and sessions, suggesting that dose alone is an incomplete organizing principle. We propose a state-first Gate-Amplifier-Reintegration framework in which awake low-dose ketamine acts primarily as an Amplifier of transient network flexibility, whereas autonomic-salience stability is treated as a candidate Gate that may shape whether this flexibility remains...

DOI: 10.3389/fnsys.2026.1880737 (opens in new tab) Ketamine Vigilance psychology Wakefulness Flexibility engineering +3

Effect of intraoperative esketamine on moderate-to-severe depressive symptoms in major surgery patients: A randomized clinical trial.

Pharmacological Research July 1, 2026 Yang Zhou, Wanchen Sun, Yuxuan Fu et al.

Perioperative depressive symptoms (PDSs) are common among patients who undergo major surgery and can lead to worse clinical outcomes. Esketamine has been reported to alleviate PDSs in patients undergoing certain types of surgery. However, there is a lack of evidence from large-scale, multisurgery studies to support its therapeutic effects in individuals with preexisting moderate-to-severe PDSs....

Acute ketamine treatment produces long-term anxiolytic effects despite increasing oxidative stress in female Wistar Kyoto rats

bioRxiv July 1, 2026 Alena Lemeshova, Feysal Abdirahaman, Haney Haidari et al. preprint

Treatment-resistant depression and anxiety remain major challenges in psychiatry, particularly in female patients, who are disproportionately affected yet remain underrepresented in preclinical ketamine research. The present study investigated short- and long-term anxiolytic effects of acute subanesthetic ketamine administration in female Wistar-Kyoto (WKY) rats, a validated genetic model of...

Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.

Fundamental and Clinical Pharmacology July 1, 2026 Nina Abukahok, Steven Lawrence, Samrachana Adhikari et al.

Ketamine is increasingly prescribed in an off-label manner to treat psychiatric disorders, raising concerns about direct-to-consumer advertising and the proliferation of clinics offering ketamine for at-home use without direct medical supervision. We aimed to identify and characterize clinics advertising ketamine for psychiatric conditions online in the New York metropolitan area (New York, New...

DOI: 10.1111/fcp.70095 (opens in new tab) Full text (opens in new tab) Ketamine Direct‐to‐consumer advertising Off‐label prescribing Telehealth

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.

JAMA Psychiatry July 1, 2026 Sung Ryul Shim, Hye Su Jeong, Tanner J. Bommersbach et al. 1 citation

While intravenous ketamine is not approved by the US Food and Drug Administration, it is increasingly used with off-label indications as a novel treatment for suicidal and depressive symptoms. To systematically review and metasynthesize the efficacy and safety data for intravenous ketamine in treating major depressive episodes (MDEs). PubMed, PsycInfo, Cochrane Library, and Embase were...

N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine.

Neuropharmacology July 1, 2026 Anne Nathalia De Sousa-Silva, Clarissa de Almeida Moura, Carina Ioná De Oliveira Torres et al. 1 citation

N,N-dimethyltryptamine (DMT) is an naturally occurring indoleamine with hallucinogenic and antidepressant effects in humans. Here, we compared the effects of DMT and S-ketamine, a fast-acting antidepressant, in helpless mice. To induce helplessness, male single and group-housed mice were exposed to inescapable footshock stress; only helpless animals were subsequently treated with S-ketamine 10...

Clinical Predictors of Antidepressant Effects of Ketamine and Esketamine in Treatment-Resistant Unipolar and Bipolar Depression: A Systematic Review

CNS Drugs July 1, 2026 Omer A. Syed, Valentyn Sobolenko, Sean M. Nestor et al.

Background and Objective Ketamine and esketamine have emerged as effective and rapid-acting interventions for treatment-resistant depression. Nevertheless, the best-suited candidates for these treatments are not clear. As such, the ability to personalize treatment selection and parameters would likely improve therapeutic response. This systematic review synthesized the literature on clinical...